Orexin receptors in GtoPdb v.2021.3

Authors

  • Paul Coleman Merck Research Laboratories
  • Luis de Lecea Scripps Research Institute
  • Anthony Gotter Merck Research Laboratories
  • Jim Hagan GlaxoSmithKline
  • Daniel Hoyer University of Melbourne https://orcid.org/0000-0002-1405-7089
  • Thomas Kilduff SRI International
  • Jyrki P. Kukkonen University of Helsinki https://orcid.org/0000-0002-6989-1564
  • Rod Porter GlaxoSmithKline
  • John Renger Merck Research Laboratories
  • Jerome M Siegel University of California Los Angeles
  • Gregor Sutcliffe Scripps Research Institute
  • Neil Upton GlaxoSmithKline
  • Christopher J. Winrow Merck Research Laboratories

DOI:

https://doi.org/10.2218/gtopdb/F51/2021.3

Abstract

Orexin receptors (nomenclature as agreed by the NC-IUPHAR Subcommittee on Orexin receptors [42]) are activated by the endogenous polypeptides orexin-A and orexin-B (also known as hypocretin-1 and -2; 33 and 28 aa) derived from a common precursor, preproorexin or orexin precursor, by proteolytic cleavage and some typical peptide modifications [109]. Currently the only orexin receptor ligands in clinical use are suvorexant and lemborexant, which are used as hypnotics. Orexin receptor crystal structures have been solved [134, 133, 54, 117, 46].

Downloads

Published

02-Sep-2021

Issue

Vol. 2021 No. 3 (2021)

Section

Summaries

How to Cite

“Orexin receptors in GtoPdb v.2021.3” (2021) IUPHAR/BPS Guide to Pharmacology CITE, 2021(3). doi:10.2218/gtopdb/F51/2021.3.